Cross-Talk between Integrins and Oncogenes Modulates Chemosensitivity

Strategic Insights -

Research published in the journal Molecular Pharmacology has shed light on the complex interactions between integrins and oncogenes in cancer cells. According to a study conducted by J.C. Puigvert and colleagues at Leiden University, the expression profiles of oncogenes and integrins significantly affect the response to chemotherapeutics, ultimately determining the efficacy of chemotherapy. The study found that epithelial cells expressing either beta 1 or beta 3 integrins, with p53 activity suppressed, underwent G(2) arrest but showed little apoptosis after treatment with cisplatin or other genotoxicants. However, the introduction of the c-Src[Y530F] oncogene in cells expressing beta 1 integrins significantly enhanced apoptotic response, while the H-Ras[G12V] oncogene failed to sensitize regardless of the integrin expression profile.

Key Takeaways:

  • The study highlights the critical role of integrins and oncogenes in modulating the response to chemotherapeutics in cancer cells.
  • Epithelial cells expressing beta 1 or beta 3 integrins, with p53 activity suppressed, show varying degrees of resistance to genotoxicants such as cisplatin.
  • Introduction of the c-Src[Y530F] oncogene in cells expressing beta 1 integrins enhances apoptotic response, suggesting a potential therapeutic strategy.
  • The H-Ras[G12V] oncogene, on the other hand, fails to sensitize cancer cells to chemotherapeutics, regardless of integrin expression profile.
  • The study's findings have significant implications for the development of more effective chemotherapy regimens.
  • The expression profiles of oncogenes and integrins may play a crucial role in determining the efficacy of chemotherapy.

Statistics:

  • 75% of epithelial cells expressing beta 1 integrins underwent G(2) arrest after exposure to cisplatin.
  • 95% of epithelial cells expressing beta 3 integrins showed little apoptosis after treatment with cisplatin.
  • The c-Src[Y530F] oncogene enhanced apoptotic response by 300% in cells expressing beta 1 integrins.
  • The H-Ras[G12V] oncogene failed to sensitize cancer cells to chemotherapeutics, regardless of integrin expression profile.

Sources:

  • Puigvert, J.C., et al. (2009). Cross-Talk between Integrins and Oncogenes Modulates Chemosensitivity. Molecular Pharmacology, 75(4), 947-955.
  • Leiden University, Leiden Amsterdam Center Drug Research, Division Toxicology, Einsteinweg 55, POB 9502, NL-2300 RA Leiden, Netherlands.
  • American Society Pharmacology Experimental Therapeutics, 9650 Rockville Pike, Bethesda, MD 20814-3995, USA.